Devin Abrahami

689 total citations
22 papers, 423 citations indexed

About

Devin Abrahami is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Devin Abrahami has authored 22 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 8 papers in Surgery and 8 papers in Oncology. Recurrent topics in Devin Abrahami's work include Diabetes Treatment and Management (8 papers), Gastroesophageal reflux and treatments (5 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). Devin Abrahami is often cited by papers focused on Diabetes Treatment and Management (8 papers), Gastroesophageal reflux and treatments (5 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). Devin Abrahami collaborates with scholars based in Canada, United States and France. Devin Abrahami's co-authors include Laurent Azoulay, Hui Yin, Emily G. McDonald, Mireille E. Schnitzer, Oriana Hoi Yun Yu, Samy Suissa, Antonios Douros, Alan Barkun, Christel Renoux and Alain Bitton and has published in prestigious journals such as Diabetes Care, Gut and BMJ.

In The Last Decade

Devin Abrahami

17 papers receiving 415 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Devin Abrahami Canada 12 172 141 105 94 89 22 423
Audrey H. H. Merry Netherlands 9 150 0.9× 58 0.4× 25 0.2× 81 0.9× 79 0.9× 15 480
Lisandro Pereyra Argentina 10 128 0.7× 54 0.4× 62 0.6× 27 0.3× 111 1.2× 34 383
Takeshi Nihei Japan 11 145 0.8× 73 0.5× 23 0.2× 77 0.8× 103 1.2× 25 371
Abdullah Çetin Türkiye 12 181 1.1× 125 0.9× 17 0.2× 72 0.8× 58 0.7× 29 423
John T. Monyak United States 11 449 2.6× 246 1.7× 110 1.0× 49 0.5× 25 0.3× 23 652
Marcus Hollenbach Germany 12 167 1.0× 27 0.2× 74 0.7× 65 0.7× 74 0.8× 54 422
Jie‐Jun Hu China 11 99 0.6× 128 0.9× 11 0.1× 77 0.8× 68 0.8× 23 466
Gennaro Clemente Italy 15 519 3.0× 116 0.8× 46 0.4× 81 0.9× 186 2.1× 48 674
Andrzej Nowak Poland 12 294 1.7× 24 0.2× 98 0.9× 25 0.3× 99 1.1× 86 533
Henning Schnell-Kretschmer Germany 12 336 2.0× 105 0.7× 25 0.2× 41 0.4× 149 1.7× 16 450

Countries citing papers authored by Devin Abrahami

Since Specialization
Citations

This map shows the geographic impact of Devin Abrahami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devin Abrahami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devin Abrahami more than expected).

Fields of papers citing papers by Devin Abrahami

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Devin Abrahami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devin Abrahami. The network helps show where Devin Abrahami may publish in the future.

Co-authorship network of co-authors of Devin Abrahami

This figure shows the co-authorship network connecting the top 25 collaborators of Devin Abrahami. A scholar is included among the top collaborators of Devin Abrahami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Devin Abrahami. Devin Abrahami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Jialing, Demissie Alemayehu, Joseph C. Cappelleri, et al.. (2025). A critical assessment of matching-adjusted indirect comparisons in relation to target populations. Research Synthesis Methods. 16(3). 569–574.
2.
3.
Bauer, Todd M., Devin Abrahami, Anna Polli, et al.. (2025). 94P: Long-term efficacy of lorlatinib vs alectinib in patients with and without brain/central nervous system metastases: Matching-adjusted indirect comparisons. Journal of Thoracic Oncology. 20(3). S67–S68.
4.
Bauer, Todd M., Devin Abrahami, Anna Polli, et al.. (2025). Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research. 15(1). e250117–e250117.
5.
Bauman, Jessica R., Geoffrey Liu, Isabel R. Preeshagul, et al.. (2024). Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer. Lung Cancer. 195. 107919–107919. 2 indexed citations
6.
Garcia, Christine, Devin Abrahami, Anna Polli, et al.. (2024). Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons. Clinical Lung Cancer. 25(7). 634–642. 4 indexed citations
7.
Abrahami, Devin, Elvira D’Andrea, Hui Yin, et al.. (2023). Contemporary trends in the utilization of second‐line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obesity and Metabolism. 25(10). 2980–2988. 18 indexed citations
8.
Abrahami, Devin, Richeek Pradhan, Hui Yin, et al.. (2023). Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study. Gut. 72(7). 1288–1295. 9 indexed citations
9.
Abrahami, Devin, Helen Tesfaye, Hui Yin, et al.. (2022). Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care. 45(12). 2907–2917. 23 indexed citations
10.
Abrahami, Devin, Emily G. McDonald, Mireille E. Schnitzer, et al.. (2021). Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut. 71(1). 16–24. 74 indexed citations
11.
Abrahami, Devin, Emily G. McDonald, Mireille E. Schnitzer, et al.. (2021). Proton pump inhibitors and risk of colorectal cancer. Gut. 71(1). 111–118. 28 indexed citations
12.
Pradhan, Richeek, Devin Abrahami, Hui Yin, et al.. (2021). Defining Clinically Relevant Target Populations Using Real‐World Data to Guide the Design of Representative Antidiabetic Drug Trials. Clinical Pharmacology & Therapeutics. 109(5). 1219–1223. 3 indexed citations
13.
Abrahami, Devin, Marie Hudson, & Samy Suissa. (2020). Statins and lower mortality in rheumatic diseases: An effect of immortal time bias?. Seminars in Arthritis and Rheumatism. 51(1). 211–218. 12 indexed citations
14.
Abrahami, Devin, Emily G. McDonald, Mireille E. Schnitzer, & Laurent Azoulay. (2020). Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study. BMJ Open. 10(12). e041529–e041529. 41 indexed citations
15.
Abrahami, Devin, Emily G. McDonald, Mireille E. Schnitzer, & Laurent Azoulay. (2020). Trends in prescribing patterns of proton pump inhibitors surrounding new guidelines. Annals of Epidemiology. 55. 24–26. 12 indexed citations
16.
17.
Abrahami, Devin, Antonios Douros, Hui Yin, et al.. (2018). Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ. 363. k4880–k4880. 47 indexed citations
18.
Abrahami, Devin, Antonios Douros, Hui Yin, et al.. (2018). Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ. 360. k872–k872. 91 indexed citations
19.
Douros, Antonios, Devin Abrahami, Hui Yin, et al.. (2018). Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. Epidemiology. 29(6). 904–912. 15 indexed citations
20.
Abrahami, Devin, Hui Yin, Oriana Hoi Yun Yu, Michaël Pollak, & Laurent Azoulay. (2017). Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes. Epidemiology. 29(2). 246–253. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Audrey H. H. Merry Breakdown of academic impact, for papers by Lisandro Pereyra Breakdown of academic impact, for papers by Takeshi Nihei Breakdown of academic impact, for papers by Abdullah Çetin Breakdown of academic impact, for papers by John T. Monyak Breakdown of academic impact, for papers by Marcus Hollenbach Breakdown of academic impact, for papers by Jie‐Jun Hu Breakdown of academic impact, for papers by Gennaro Clemente Breakdown of academic impact, for papers by Andrzej Nowak Breakdown of academic impact, for papers by Henning Schnell-Kretschmer
Rankless by CCL
2026